What is the GLOW Peptide Blend? GHK-Cu, BPC-157, and TB-500 Explained
Compound Spotlight
The GLOW Blend combines GHK-Cu, BPC-157, and TB-500. Of the three, GHK-Cu is the one with the deepest research history and the strongest human evidence — and it is also the most chemically unusual, because it is not really a peptide acting alone but a peptide-copper complex in which the metal is essential to the function.
Quick summary
- GHK-Cu is a tripeptide (Gly-His-Lys) bound to copper(II). The copper is not an additive — it is part of the active molecule.
- Isolated from human plasma by Loren Pickart in the 1970s; plasma levels decline substantially with age.
- Copper is a required cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin — a direct link to matrix biology.
- GHK-Cu has the best human evidence of any component here, though largely from topical dermatological research.
- BPC-157 and TB-500 contribute angiogenesis and cell-migration mechanisms respectively, both preclinical.
- The three-way combination itself has not been evaluated in controlled research.
GHK-Cu: the copper is the point
GHK is three amino acids: glycine, histidine, lysine. On its own it is unremarkable. What makes it biologically interesting is that the histidine imidazole ring, together with the terminal amine and the peptide backbone, forms an exceptionally good binding site for copper(II) ions.
This matters because free copper is dangerous. Unbound copper ions catalyze Fenton-type reactions that generate hydroxyl radicals, which is why the body keeps essentially no free copper in circulation and instead transports it bound to carrier molecules. GHK-Cu appears to function as one such carrier: it holds copper in a form that can be delivered to enzymes that need it, without letting it run loose and cause oxidative damage.
Copper is a required cofactor for several enzymes directly relevant to tissue structure. Lysyl oxidase catalyzes the cross-linking of collagen and elastin fibers — without it, connective tissue does not achieve tensile strength. Copper-zinc superoxide dismutase is a primary antioxidant enzyme. Cytochrome c oxidase is the terminal complex of the electron transport chain. A molecule that delivers copper safely therefore has plausible mechanistic reach into structural, antioxidant, and energetic biology at once.
Discovery and decline with age
Loren Pickart identified GHK in human plasma in the early 1970s while investigating why blood from younger donors behaved differently from older donors in liver tissue culture. That framing — a factor present in young plasma and diminished in old — is why GHK-Cu has been a fixture in aging research ever since. Reported plasma concentrations fall from roughly 200 ng/mL around age 20 to substantially lower levels by age 60.
Documented activities include stimulation of collagen, elastin, decorin and glycosaminoglycan synthesis, modulation of matrix metalloproteinases and their inhibitors (the enzymes that break matrix down, and the brakes on those enzymes), and effects on wound healing and hair follicle biology. Gene-expression profiling work has reported that GHK influences expression across a very large number of human genes, which is striking, though broad transcriptional effects are also harder to interpret than a single defined pathway.
The evidence, and its shape
GHK-Cu has the most substantial human evidence base of the three components, accumulated over decades — but the great majority of it concerns topical application in dermatological and cosmetic contexts, where it has been studied for skin firmness, wrinkle depth, and wound healing. That is real evidence, and it is evidence about a specific route of administration. It does not automatically transfer to systemic use, and the distinction is worth holding onto.
One further caution specific to this compound: copper is essential but toxic in excess, and the body regulates total copper load tightly. Anyone with a copper metabolism disorder such as Wilson’s disease is in a categorically different situation with respect to any copper-delivering compound.
The other two components
BPC-157 is a 15-amino-acid sequence derived from a protein in human gastric juice, associated in preclinical work with VEGF-mediated angiogenesis, nitric oxide signaling, and focal adhesion kinase pathways. Its literature is extensive but concentrated in one research group at the University of Zagreb, and controlled human trials are essentially absent. It is WADA-prohibited and was designated an FDA Category 2 bulk substance in 2023.
TB-500 is a synthetic fragment of Thymosin Beta-4 corresponding to its actin-binding domain — not the complete 43-amino-acid protein, despite frequent description as such. Actin regulation governs cell migration, which is required for cells to populate a repair site.
Both are covered in more depth in our Wolverine Blend breakdown.
The combination rationale
The stated logic maps the three onto distinct requirements of tissue repair: GHK-Cu for matrix synthesis and remodeling, BPC-157 for blood supply, TB-500 for cell mobility. Structure, supply, and mobility.
The reasoning is coherent, but it remains reasoning. No controlled study has evaluated this three-component combination, compared it against its individual components, or characterized interactions between them. Fixed-ratio blends also prevent varying one component independently, which limits what any observation can attribute to what.
Frequently asked questions
Why does GHK need to be bound to copper?
The copper is functionally central. GHK’s proposed role is safe copper delivery to enzymes that require it as a cofactor, such as lysyl oxidase. The peptide-copper complex, not the bare peptide, is the active entity.
How does GLOW differ from KLOW?
KLOW is GLOW plus KPV, an anti-inflammatory tripeptide. GLOW contains GHK-Cu, BPC-157, and TB-500.
Which component has the best evidence?
GHK-Cu, by a clear margin — decades of research including human studies, though predominantly topical rather than systemic.
How do I know what is actually in the vial?
Every lot we sell has a published Certificate of Analysis from an independent, third-party lab confirming identity and purity. For blends this is more important than usual, since the COA verifies the composition of the specific combination.
References
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987.
- Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells. Nature New Biology. 1973;243:85–87.
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2011.
- Goldstein AL, et al. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421–429.
View the GLOW Blend product listing → | View GHK-Cu →
Read our BPC-157 and TB-500 breakdown →
Look up your lot Certificate of Analysis →
For laboratory and research use only. Not for human consumption. No component of this blend is approved by any regulatory authority, and BPC-157 is prohibited by WADA. This article summarizes published research for informational purposes and is not medical advice, nor a recommendation or protocol for use.
Related research compounds
Arc Peptides supplies these compounds, each third-party tested for purity and identity with a lot-specific Certificate of Analysis:
For laboratory research use only. Not for human consumption.
